The content of the -subunit of the ATP synthase ( -F 1 -ATPase), which forms the catalytic site of the enzyme ATP synthase, is reduced in muscle of obese humans, along with a reduced capacity for ATP synthesis. We studied 18 young (37 ± 8 years) subjects of which nine were lean (BMI = 23 ± 2 kg m −2 ) and nine were obese (BMI = 34 ± 3 kg m −2 ) to determine the fractional synthesis rate (FSR) and gene expression of -F 1 -ATPase, as well as the specific activity of the ATP synthase. FSR of -F 1 -ATPase was determined using a combination of isotope tracer infusion and muscle biopsies. Gene expression of -F 1 -ATPase and specific activity of the ATP synthase were determined in the muscle biopsies. When compared to lean, obese subjects had lower muscle -F 1 -ATPase FSR (0.10 ± 0.05 vs. 0.06 ± 0.03% h −1 ; P < 0.05) and protein expression (P < 0.05), but not mRNA expression (P > 0.05). Across subjects, abundance of -F 1 -ATPase correlated with the FSR of -F 1 -ATPase (P < 0.05). The specific activity of muscle ATP synthase was lower in obese compared to lean subjects (0.035 ± 0.004 vs. 0.042 ± 0.007 arbitrary units; P < 0.05), but this difference was not significant after the activity of the ATP synthase was adjusted to the -F 1 -ATPase content (P > 0.05). Obesity impairs the synthesis of -F 1 -ATPase in muscle at the translational level, reducing the content of -F 1 -ATPase in parallel with reduced capacity for ATP generation via the ATP synthase complex.
INTRODUCTION
Obesity is linked to insulin resistance to glucose metabolism in skeletal muscle, but the effects of obesity on the regulation of energy metabolism and production rate of associated proteins in skeletal muscle are less clear. Magnetic resonance spectroscopy studies have shown that obese (Newcomer, Larson-Meyer, Hunter, & Weinsier, 2001 ) and insulin-resistant (Petersen, Dufour, Befroy, Garcia, & Shulman, 2004) individuals have a lower capacity for muscle adenosine triphosphate (ATP) turnover in vivo. Lower capacity for muscle ATP production in humans with obesity has also been reported in studies using in vitro mitochondrial respiration assays (Abdul-Ghani et al., 2009; Chanseaume et al., 2010) . Furthermore, a lower concentration of ATP has been reported in the skeletal muscle of obese individuals (Lennmarken, Sandstedt, von Schenck, & Larsson, 1986) . In muscle, the mitochondrial enzyme ATP synthase is responsible for more than c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society 90% of the ATP produced in that tissue, and recent evidence indicates that it plays a key role in metabolic disorders by regulating substrate metabolism (Formentini et al., 2017) . From a functional standpoint, the -subunit of the ATP synthase ( -F 1 -ATPase) forms the catalytic site of the ATP synthase, and therefore has a direct role among the rest of the subunits of the enzyme in determining the capacity for ATP production.
Characteristically, lower -F 1 -ATPase expression is associated with lower ATP content in liver in animal models of diabetes (Wang et al., 2014) .
Previous research has documented that obese, insulin-resistant individuals have reduced content of -F 1 -ATPase in skeletal muscle (Hojlund et al., 2010; Hwang et al., 2010; Tran et al., 2016) . Reduced -F 1 -ATPase content in the muscle of individuals with excess adiposity or insulin resistant could, therefore, contribute to the reduced capacity for ATP synthesis previously observed in the muscle of such individuals (Abdul-Ghani et al., 2009; Chanseaume et al., 2010; Newcomer et al., 2001; Petersen et al., 2004) . In addition, antibodies directed against the -F 1 -ATPase inhibit ATP generation in vitro (Moser et al., 2001) , further underlying the critical role of -F 1 -ATPase in the synthesis of ATP. The mechanisms that contribute to the reduced content of -F 1 -ATPase in the skeletal muscle of obese individuals are not known.
Furthermore, whether the production rate of -F 1 -ATPase in skeletal muscle can directly be linked to impaired activity of the ATP synthase enzyme remains speculative.
Measurements of the content of -F 1 -ATPase in skeletal muscle provide only a static snapshot of the metabolism of -F 1 -ATPase in muscle. On the other hand, measurement of the rate of production of -F 1 -ATPase in skeletal muscle provides direct information on the turnover rate of the -F 1 -ATPase in muscle. Therefore, the underlying mechanism(s) behind the reduced content of muscle -F 1 -ATPase in obesity can be directly investigated only by performing dynamic, real time measurements, such as by determining the rate of synthesis of muscle -F 1 -ATPase, in vivo. Recent studies have reported fractional synthesis rate (FSR) of human muscle -F 1 -ATPase under a variety of circumstances (Murphy et al., 2018; Shankaran et al., 2016) , but none of them have investigated the effects of obesity. We have established a procedure that allows quantifying the FSR of muscle -F 1 -ATPase based on the incorporation of a stable isotope amino acid tracer in the protein and in combination with the use of high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Everman et al., 2011) .
We hypothesized that reduced content of -F 1 -ATPase in muscle of obese individuals is associated with reduced rate of synthesis of -F 1 -ATPase. In addition to its importance in maintaining the quantity of muscle -F 1 -ATPase, a given rate of synthesis of -F 1 -ATPase is also important in maintaining the quality of the protein by renewing the -F 1 -ATPase pool within skeletal muscle. Because older molecules of a protein are more prone to metabolic damage than newer ones (Jaleel et al., 2010) , decrease in the rate of synthesis of muscle -F 1 -ATPase can lead to accumulation of older -F 1 -ATPase molecules that are in a modified/less functional state. Therefore, we also hypothesized that reduced synthesis rate of muscle -F 1 -ATPase is observed together with reduced specific activity of the ATP synthase enzyme.
METHODS

Ethical approval
All study procedures conformed to the standards set by the Declaration of Helsinki and were approved by the Institutional Review Board at Mayo Clinic (IRB No.: 12-004000). Risks stemming from participation in the study were described to each study participant before obtaining written consent. The study was registered at ClinicalTrials.gov (NCT01824173).
Subjects
Subjects were asked to participate in the study if they were apparently healthy as determined by an initial screening over the phone and had body mass index (BMI) of >30 kg m −2 (i.e. obese) or <25 kg m −2 (i.e.
New Findings
• What is the central question of this study?
Humans with obesity have lower ATP synthesis in muscle along with lower content of the -subunit of the ATP synthase ( -F1-ATPase), the catalytic component of the ATP synthase. Does lower synthesis rate of -F1-ATPase in muscle contribute to these responses in humans with obesity?
• What is the main finding and its importance?
Humans with obesity have a lower synthesis rate of -F 1 -ATPase and ATP synthase specific activity in muscle.
These findings indicate that reduced production of subunits forming the ATP synthase in muscle may contribute to impaired generation of ATP in obesity. lean). Exclusion criteria for study participation included diabetes, heart disease, peripheral vascular disease, history of liver or kidney disease, smoking, participation in a weight-loss regimen, and use of medications or nutritional supplements. Only subjects that took part in various physical activities ≤2 per week were invited in the study (i.e. sedentary individuals). A comprehensive screening was later performed at the Clinical Studies Infusion Unit (CSIU) at Mayo Clinic in Scottsdale, AZ, USA, to determine further eligibility for participation in the study.
It included a medical history/physical examination, resting electrocardiogram, standard blood and urine tests, as well as an oral glucose tolerance test (OGTT). Plasma glucose and insulin concentration values during the OGTT were used to estimate the subjects' insulin sensitivity by calculating the Matsuda insulin-sensitivity index as described previously (Matsuda & DeFronzo, 1999) .
Body composition was determined using bioelectrical impedance analysis (BIA 310e, Biodynamics Corp., Shoreline, WA, USA), and the waist-to-hip ratio was calculated by measuring the circumferences at the level of the umbilicus and the buttocks. Peak oxygen uptake (V O 2 peak ) was measured using a cycle ergometer, and by incrementally increasing the workload (20 W min −1 ) to volitional exhaustion while continuously monitoring the expired gases (MedGraphics Metabolic Cart, Saint Paul, MN, USA).
Experimental protocol
Subjects that qualified for the study took part in a single infusion trial performed at the CSIU. Prior to their participation in the infusion trial, subjects were instructed to avoid any exercise, maintain a regular diet, and avoid alcohol consumption during the 3 days leading to the infusion trial. Subjects arrived at the CSIU at ∼07.00 h after an overnight fast.
Compliance with the diet and exercise instructions indicated above was confirmed with each study participant before the initiation of the experimental procedures.
Experimental procedures were initiated by first inserting two catheters: one into a hand vein for obtaining blood samples and another one into an antecubital vein of the opposite arm for infusion of a stable isotope of an amino acid. L-[2,3,3,4,5,5,5,6,6,6-2 H 10 ]Leucine (Cambridge Isotope Laboratories, Inc., Tewksbury, MA, USA) was infused (constant rate, 0.15 mol (kg fat-free mass (FFM)) −1 min −1 ; prime, 6.4 mol (kg FFM) −1 ) throughout the experimental protocol to enrich the muscle free amino acid pool with labelled leucine and measure the rate of synthesis of muscle proteins. Synthesis rate of muscle proteins was measured by determining the stable isotopic enrichment of the proteins with d 9 -leucine, as we have previously described (Tran, Masters, Roust, & Katsanos, 2015) . Biopsy samples were collected from the vastus lateralis muscle at 120 and 300 min after the start of the labelled leucine infusion. Following removal of visible fat and connective tissue, samples were blotted dry and stored in liquid nitrogen until analyses. Blood samples were collected for the determination of labelled leucine and various blood chemistry variables prior to the initiation of the infusion and again at 110, 115, 140, 260, 280 and 300 min following the start of the labelled leucine infusion.
Analyses of samples
Preparation of samples for stable isotope enrichment determination
The isotopic enrichment of blood and mixed-muscle protein with d 9 -leucine, expressed as molar percent excess (MPE), was measured using HPLC-MS/MS, by first isolating the amino acids and following procedures similar to those we have used in the past (Tran et al., 2015) .
Blood samples collected during the infusion study was transferred into glass tubes containing 15% sulfosalicylic acid (SSA) and the tubes were vortexed several times. These tubes were then centrifuged at 2500 g for 15 min at 4 • C, and the supernatant containing the amino acids was collected. These amino acids were isolated using cationexchange columns (AG 50W-8X 100-200-mesh; Bio-Rad Laboratories, Inc., Hercules, CA, USA), which were conditioned with 3 ml of 2 M NH 4 OH and 3 ml of 1 M HCl prior to the addition of the samples (i.e. 500 l of the blood-SSA mixture supernatant). The amino acids were eluted from the columns using 8 ml of 2 M NH 4 OH. Proteins in the muscle samples (i.e. ∼15 mg of tissue) were precipitated using 500 l of 5% SSA. The samples were homogenized, centrifuged at 2500 g for 45 min at 4 • C, and the resulting pellet was collected. The samples were washed with 500 l of 5% SSA two more times, and prior to collection of the final pellet that included the muscle proteins. This pellet was first washed with 1 ml of ethanol and then with 1 ml of ethyl ether, and it was then left to dry overnight at 50 • C. Proteins in these samples were hydrolysed with 6 M HCl at 110 • C over 24 h. The protein hydrolysate was added to cation-exchange columns (AG 50W-8X 200-400-mesh; Bio-Rad Laboratories), following conditioning of the columns as described for blood (above), and in order to isolate/purify the amino acids from the proteins in the muscle samples. The amino acids were eluted from the columns with 8 ml of 2 M NH 4 OH.
Tryptic peptides for the determination of d 9 -leucine enrichment of -F 1 -ATPase were produced after purification of the muscle -F 1 -ATPase (Everman et al., 2011) . Specifically, following homogenization of the muscle (see 'Protein immunoblot assays' section below), muscle -F 1 -ATPase was purified from the homogenate using immunoprecipitation. First, a mouse monoclonal -F 1 -ATPase-specific antibody (cat. no. ab5432, RRID:AB_304883, Abcam, Cambridge, MA, USA) was coupled to protein G agarose beads, and by rotation of the antibody/bead mixture for 1 h at room temperature. After antibodybead conjugation, 6 mg of whole-muscle lysate protein and homogenization buffer were added to the mixture, which was incubated overnight at 4 • C. The beads were subsequently washed four times with PBS and the proteins were denatured and eluted from the beads by incubation for 30 min at 37 • C in 17 l of SDS-containing loading buffer.
The immunoprecipitated protein was resolved using 10% SDS-PAGE, and a band corresponding to -F 1 -ATPase was excised from the gel and cut into small pieces. The gel pieces were placed into microcentrifuge tubes and washed with 400 l of deionized water. Coomassie stain was removed by washing two times with 300 l of 50% acetonitrile (ACN) in 40 mM NH 4 HCO 3 , and the gel pieces were dehydrated with 100% ACN. The ACN was removed and the gel pieces were dried further in a vacuum centrifuge at 62 • C for 30 min. Peptides in the samples were generated by using trypsin (250 ng) in 40 mM NH 4 HCO 3 and the digestion left to continue overnight at 37 • C. The digestion was stopped using 5% formic acid (FA). Following incubation of the samples at 37 • C for 30 min and brief centrifugation for 1 min the collected supernatant was transferred to a clean polypropylene tube. The peptides were purified using solid-phase extraction (C18 ZipTip; Millipore, Billerica, MA, USA) after sample loading in 0.05% heptafluorobutyric acid-5% FA and elution with 4 l 50% ACN-1% FA and 4 l 80% ACN-1%
FA. The eluates were combined and after the volume of the sample was reduced (i.e. ∼2 l) by vacuum centrifugation, 20 l of 0.05% heptafluorobutyric acid-1% FA-2% ACN was added to the sample.
Stable isotope enrichment determination by mass spectrometry
The isotopic enrichment of amino acids was measured by LC-MS/MS, using the isobutyl ester derivative of the amino acids (Tran et al., 2015) .
In the blood samples, selected reaction monitoring was applied for 
Protein immunoblot assays
Muscle (∼ 70 mg) was homogenized in ice-cold freshly prepared buffer (1 ml/100 mg tissue) containing Tris-HCl (20 mM) pH 7.5, NaCl (150 mM), Na 2 EDTA (1 mM), EGTA (1 mM), NP-40 (1%), sodium deoxycholate (1%), sodium pyrophosphate (2.5 mM), -glycerophosphate (1 mM), Na 3 VO 4 (1 mM) and leupeptin (1 g ml −1 ).
Following centrifugation at 14,000 g for 15 min at 4 • C, aliquots of the supernatant were stored at −80 • C for further sample analyses.
Protein concentration in the muscle homogenates was determined by the method of Lowry (Lowry, Rosebrough, Farr, & Randall, 1951) , and -F 1 -ATPase abundance was quantified using immunoblotting (Tran et al., 2016 
mRNA quantification assays
Determination of - 
ATP synthase specific activity
ATP synthase specific activity was measured in muscle homogenates using a commercially available enzyme activity assay kit (cat. no.
ab109716, Abcam). After addition of 50 g of protein from muscle homogenate into microplate wells, the enzyme was immunocaptured within the wells using pre-coated antibodies. Its activity was measured as the rate of ATP hydrolysis to ADP, where ultimately production of ADP is coupled to the oxidation of NADH to NAD + , and monitored as the decrease in absorbance at 340 nm (i.e. nm min −1 per amount of sample loaded into the well). The quantity of the enzyme captured in each well was measured by adding an ATP synthase-specific antibody conjugated with alkaline phosphatase. The quantity of the ATP synthase was measured as the change in absorbance at 405 nm (i.e.
nm min −1 per amount of sample loaded into the well). Therefore, ATP synthase specific activity was calculated as the ratio of the absorbance at 340 nm to that at 405 nm, and is reported as arbitrary units. 
Plasma biochemical assays
Calculations
Protein FSR (% h −1 ) was determined by the precursor-product approach using the measured d 9 -leucine isotopic enrichment in blood and the muscle protein(s) of interest (i.e. -F 1 -ATPase, mixed-muscle protein) (Tran et al., 2015) . The specific activity of ATP synthase was calculated as arbitrary units describing the change in the optical density associated with the activity of the enzyme over the change in the optical density associated with the quantity of the enzyme (i.e. change in alkaline phosphatase activity). Measured -F 1 -ATPase mRNA levels were normalized to GAPDH and responses between groups were compared using the comparative C T method (2 −ΔΔC T ).
Statistical analyses
Data were normally distributed based on the D'Agostino-Pearson and Shapiro-Wilk normality tests. Measurements between lean and obese groups were compared using Student's unpaired t test. Pearson's product-moment correlation coefficient (r) was calculated to test the strength of association between variables of interest. Significant difference was set at P ≤ 0.05, and data are presented as the mean ± SD. Statistical analyses were performed using Prism version 7.0 software (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
Subject characteristics
Based on the anthropometric characteristics and blood chemistry profiles of the lean and obese subjects showed in Table 1 , the two groups represented typical populations of lean individuals and individuals with obesity. As expected, obese subjects were insulin resistant to glucose metabolism based on OGTT-estimated insulin sensitivity. However, the two groups did not differ in aerobic fitness based on theirV O 2 peak responses (Table 1) .
-F 1 -ATPase synthesis rate
Average blood leucine enrichment (MPE) was not different between the lean (4.1 ± 0.8) and obese (4.3 ± 0.4) groups during the experimental period (P > 0.05). Synthesis rate of -F 1 -ATPase was lower in the muscle of the obese subjects ( Figure 1a ; P < 0.05), along with lower synthesis rate of mixed-muscle protein (Figure 1b; P < 0.05). Mixed-muscle protein synthesis is the most commonly reported measure of protein synthesis in skeletal muscle reflecting the average rate of the synthesis of all proteins within the muscle homogenate. Data on mixed-muscle protein synthesis from some of the subjects studied in the present study have been recently published
TA B L E 1 Subject characteristics
Lean (3 M/6 F) Obese (5 M/4 F)
Age (years) 37 ± 8 3 7 ± 9
Weight (kg) 66 ± 12 100 ± 13* BMI (kg m −2 ) 2 3 ± 2 3 4 ± 3* Fat free mass (kg) 50 ± 11 66 ± 9* Body fat (%) 25 ± 8 3 3 ± 8* (Tran et al., 2018) . Although not the focus of the present studies, the synthesis rate of mixed-muscle protein is provided herein for comparison purposes with that of -F 1 -ATPase. The synthesis rate (% h −1 ) of -F 1 -ATPase (0.104 ± 0.05) tended to be higher than that of the mixed-muscle protein (0.079 ± 0.02) in the lean (P = 0.08) but not in the obese (0.063 ± 0.03 vs. 0.059 ± 0.01; P = 0.32) subjects. The ratio of -F 1 -ATPase synthesis rate to mixed-muscle protein synthesis rate, however, did not differ between lean (1.3 ± 0.6) and obese (1.1 ± 0.5) subjects (P > 0.05). Across subjects, synthesis rate of -F 1 -ATPase correlated with that of mixed-muscle protein (r = 0.46; P = 0.05).
Furthermore, synthesis rate of -F 1 -ATPase correlated inversely with the plasma insulin concentration (r = −0.49; P < 0.05), but not with the insulin sensitivity to glucose metabolism (i.e. Matsuda index; P > 0.05).
-F 1 -ATPase gene expression
As expected, protein expression of -F 1 -ATPase was lower in the obese subjects (Figure 2a ; P < 0.05). However, mRNA expression of -F 1 -ATPase was not different between lean and obese subjects and obese (18.6 ± 27.4) subjects (P > 0.05).
ATP synthase specific activity
The specific activity of the ATP synthase complex was lower in the obese subjects (Figure 4 ; P < 0.05). However, the specific activity of the enzyme was not different between the lean and obese subjects when adjusted to the -F 1 -ATPase expression (P > 0.05). There was no correlation between the synthesis rate of -F 1 -ATPase and the specific activity of the ATP synthase (P > 0.05).
DISCUSSION
The rate of synthesis determined in vivo provides the most direct measure of the rate of biogenesis and renewal of any given protein, in F I G U R E 4 ATP synthase specific activity in skeletal muscle of lean and obese subjects. ATP synthase activity was measured as the rate of ATP hydrolysis to ADP, ultimately coupled to the oxidation of NADH to NAD + and monitored as the change in absorbance at 340 nm (i.e. nm min −1 per amount of sample loaded into the well). The quantity of the enzyme was measured using an ATP synthase-specific antibody conjugated with alkaline phosphatase, and by monitoring the change in absorbance at 405 nm (i.e. nm min −1 per amount of sample loaded into the well). ATP synthase specific activity was calculated as the ratio of the absorbance at 340 nm to that at 405 nm and is reported as arbitrary units. Values are means ± SD. *P < 0. Mixed-protein synthesis traditionally measured in skeletal muscle reflects an average rate of synthesis across all muscle proteins, whose individual rates, however, differ considerably within the skeletal muscle (Jaleel et al., 2008; Shankaran et al., 2016) . Previous research has shown almost twofold higher synthesis rate of mixed-mitochondrial protein when compared to the synthesis rate of mixed-muscle protein in skeletal muscle of young, healthy humans (Rooyackers, Adey, Ades, & Nair, 1996) . The synthesis rate of the mitochondrial -F 1 -ATPase in the present study was, however, only 35% higher than that of the mixed-muscle protein. This observation is in line with findings in rodents, and where the synthesis rate of -F 1 -ATPase is closer to that of mixed-muscle protein when compared to other mitochondrial proteins (Jaleel et al., 2008) . The FSR of -F 1 -ATPase in our healthy sedentary lean humans (0.10 ± 0.05% h −1 ) was higher than that previously reported in either healthy sedentary (∼ 0.05% h −1 ) (Shankaran et al., 2016) or older overweight/obese (∼ 0.03% h −1 ) (Murphy et al., 2018) humans. In the latter studies, FSR of -F 1 -ATPase was measured using oral consumption of deuterated water. Although measurement of protein FSR using deuterated water compares well under certain circumstances with that using the traditional approach that is based on the incorporation of labelled amino acids into protein (Wilkinson et al., 2015b) , the deuterated water approach appeared previously to either overestimate (Murphy et al., 2018) or underestimate (Wilkinson et al., 2015b ) muscle protein FSR. There is still considerable debate with respect to the details describing the application of the deuterated water approach to accurately measure muscle protein FSR (Fluckey et al., 2015; Wilkinson, Atherton, Phillips, Greenhaff, & Smith, 2015a) . To our knowledge, our study is the first to report the FSR of human muscle -F 1 -ATPase using the rather well-established amino acid tracer technique to measure the synthesis rate of a protein in skeletal muscle.
By measuring the synthesis rate of -F 1 -ATPase we show that the production rate of -F 1 -ATPase is a defect contributing to the reduced content of -F 1 -ATPase in the skeletal muscle of obese, insulin-resistant humans. The synthesis rate of -F 1 -ATPase showed significant positive correlation with that of mixed-muscle protein across all subjects, and the ratio of -F 1 -ATPase synthesis rate to mixed-muscle protein synthesis rate did not differ between lean and obese subjects. These findings suggest that underlying mechanism(s) responsible for the decrease in the synthesis rate of - The primary role of mitochondrial proteins in muscle is to defend against challenges in energy homeostasis by generating ATP. We found that the specific activity of the ATP synthase is reduced in muscle of obese individuals, which is in line with recent findings on the activity of this enzyme determined in primary culture of skeletal muscle cells from obese subjects (Formentini et al., 2017) . Moreover, previous research has documented a reduced rate of ATP synthesis determined in vivo in muscle of individuals with increased body fat (Newcomer et al., 2001 ) and insulin resistance (Petersen et al., 2004) .
Our findings show that obesity and the associated insulin resistance impair specifically the function of the mitochondrial ATP synthase, and that this effect is seen together with reduced abundance of its catalytic -F 1 -ATPase subunit. Although the specific activity of the ATP synthase was reduced in muscle samples from the obese subjects, it was not different between the lean and the obese subjects when adjusted to the immunoblot-determined -F 1 -ATPase expression. This latter observation would be consistent with a notion that the capacity of the ATP synthase enzyme is not altered in obesity/insulin resistance, unless the content of its individual subunits is reduced in the metabolic setting of human obesity. Moreover, lack of correlation between the synthesis rate of -F 1 -ATPase and the specific activity of the ATP synthase suggests that the synthesis, and thus renewal, rate of -F 1 -ATPase is not a direct determinant of the capacity of the ATP synthase to generate ATP. In line with this observation, discordance between mixed-mitochondrial protein synthesis rate (i.e. increased) and mitochondrial oxidative capacity (i.e. decreased) has been previously shown in muscle of rodents (Chanseaume et al., 2007) . Therefore, our overall findings show that lower capacity for ATP synthesis in muscle of obese, insulin-resistant humans is the result of a decrease in the abundance of muscle -F 1 -ATPase, rather than impaired turnover rate of -F 1 -ATPase per se in the muscle of these individuals.
It is likely that the rates of synthesis of other subunits of the muscle ATP synthase complex previously shown also to be lower in obesity, such as the -F 1 -ATPase (Formentini et al., 2017; Hojlund et al., 2010) , are reduced in obese, insulin-resistant humans. Given the amount of tissue biopsy required to determine the stable isotope enrichment of individual proteins using the experimental approach of the present study, it was not feasible to measure the synthesis rate across all the subunits of the ATP synthase complex. Nevertheless, recent evidence shows that not all of the currently characterized 17 subunits forming the ATP synthase complex (Fujikawa, Sugawara, Tanabe, & Yoshida, 2015) are decreased in obesity (Formentini et al., 2017) . ATPase is due to lower synthesis rate of muscle -F 1 -ATPase, given the significant correlation we observed between muscle -F 1 -ATPase content and muscle -F 1 -ATPase synthesis rate across the study subjects.
In the present study, the synthesis rate of -F 1 -ATPase did not correlate with the insulin sensitivity, as estimated from the OGTTdetermined Matsuda insulin sensitivity index (Matsuda & DeFronzo, 1999) . This implies that insulin sensitivity to glucose metabolism is not a direct factor on regulating the synthesis rate of mitochondrial -F 1 -ATPase under basal/non-insulin-stimulated conditions. On the other hand, we have previously shown that exposure of primary muscle cells to fatty acids reflecting a plasma free fatty acid profile representative of human obese phenotype decreases the protein expression of -F 1 -ATPase (Tran et al., 2016) . Under those conditions, the decrease in -F 1 -ATPase expression was observed together with increased expression of a specific microRNA (i.e. miR-127-5p) (Tran et al., 2016) .
Also, experiments in -cell lines show that lipotoxicity, which is a common manifestation in skeletal muscle of individuals with obesity (Coen et al., 2010) , decreases -F 1 -ATPase expression in parallel with the decrease in intracellular ATP concentrations (Kohnke, Mei, Park, York, & Erlanson-Albertsson, 2007) . Such evidence suggests that the metabolic environment associated specifically with lipid metabolism in obesity/insulin resistance may be a primary factor contributing to the reduced muscle -F 1 -ATPase by interfering with the -F 1 -ATPase mRNA translation, and ultimately suppressing the capacity for ATP synthesis in humans with obesity.
Impaired ATP synthase activity may not only decrease muscle ATP levels as previously reported in obesity (Lennmarken et al., 1986) , but also play a role in determining insulin sensitivity. Although whether impairments in mitochondrial function are a cause or consequence of insulin resistance is still controversial, impaired ATP synthase activity linked to lower -F 1 -ATPase content reduces fatty acid oxidation in skeletal muscle cells resulting in lipid accumulation in the cytosol (Formentini et al., 2017) . Reduced oxidation of fatty acids is indeed a manifestation of impaired substrate metabolism in muscle of obese individuals (Kim, Hickner, Cortright, Dohm, & Houmard, 2000) , resulting in accumulation of lipid mediators such as diacylglycerols in the cytosol that interfere with the insulin signalling (Montgomery & Turner, 2015) . Impaired ATP synthase function may also increase reactive oxygen species (ROS) production, similar to the increase in ROS production when the ATP synthase is experimentally inhibited in vitro by oligomycin (Roy et al., 2008) . In turn, ROS production can interfere with insulin signalling in muscle (Henriksen, DiamondStanic, & Marchionne, 2011) . Furthermore, decreased capacity for ATP synthesis and associated lipid oxidation in the muscle of obese individuals can lead to decreased capacity for physical activity (Rogge, 2009) , which is evident in people with obesity (Cooper, Page, Fox, & Misson, 2000) , decreasing total daily energy expenditure and exasperating weight gain in individuals with obesity (Ravussin et al., 1988) .
Studies employing animal models show that physical exercise can upregulate the content of -F 1 -ATPase in muscle (Gonzalez, Hernando, & Manso, 2000) . Also, exercise training in lean, healthy humans upregulates muscle ATP synthase flux (Kacerovsky-Bielesz et al., 2009) . Given this evidence, and despite studying sedentary individuals with aerobic fitness (i.e.VO 2peak ) that was comparable between groups, we cannot exclude the possibility that subjects with obesity had lower overall fitness and/or physical activity levels. Therefore, and given that it was not experimentally feasible to characterize the everyday physical activity patterns of our subjects in a definitive manner, our study is possibly limited in its ability to attribute the observed findings on -F 1 -ATPase metabolism and ATP synthase activity on obesity per se.
CONCLUSIONS
We show a lower rate of synthesis of -F 1 -ATPase, which forms the catalytic subunit of the enzyme responsible for ATP generation, in skeletal muscle of humans with obesity/insulin resistance. Lower rate of synthesis of -F 1 -ATPase is associated with lower content of -F 1 -ATPase, which in turn appears to contribute to reduced capacity for ATP generation via the ATP synthase in the muscle of humans with obesity/insulin resistance.
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